Charity dedicated to the fight
against childhood cancer
against childhood cancer
Although France is among the most protective countries in the world in terms of healthcare coverage, children with certain rare or serious illnesses have low, or even nonexistent, chances of recovery due to a lack of treatments developed specifically for them. How can we accept that an entire segment of society is ignored due to the lack of development of treatments tailored to this population, for purely economic reasons? This question motivated Marie Recalde's commitment.
Faced with this legitimate indignation, the MP agreed to introduce a bill aimed at setting up a support program for therapeutic innovation against cancers, rare diseases and orphan diseases in children.
Every year, more than 500 children and adolescents die from pediatric cancers. It is the leading cause of death from disease in France and Europe. The development of treatments specifically tailored to children, particularly in severe cases, remains clearly insufficient.
While the availability of medicines for children has improved in some therapeutic areas thanks to the European pediatric regulation, these positive developments often remain linked to developments in the adult market.
Thus, children only benefit from therapeutic advances when adult needs or market expectations coincide with pediatric needs. Marie Recalde refuses to let pediatric development depend solely on the accounting strategies of large pharmaceutical companies.
The bill proposed by Marie Recalde envisions a small tax levied on the revenue of pharmaceutical companies that market drugs reimbursed by national health insurance. The revenue from this tax would be allocated to an investment fund dedicated to financing pediatric drug startups, with a focus on cancers and rare, incurable diseases, or those with a poor prognosis.
